Kymera Therapeutics (KYMR, Financial) has scheduled a video webcast for Friday, May 9, 2025. During the event, the company will present its financial outcomes for the first quarter of 2025. Additionally, Kymera plans to introduce a new oral development candidate aimed at addressing a previously untargeted, high-value target relevant to multiple autoimmune and rheumatic diseases.
The webcast will also offer insights into the company's advancements and strategic milestones within its leading immunology pipeline. Stakeholders and interested parties can anticipate an in-depth overview of Kymera's initiatives and future directions.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 18 analysts, the average target price for Kymera Therapeutics Inc (KYMR, Financial) is $58.33 with a high estimate of $97.00 and a low estimate of $41.00. The average target implies an upside of 90.07% from the current price of $30.69. More detailed estimate data can be found on the Kymera Therapeutics Inc (KYMR) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Kymera Therapeutics Inc's (KYMR, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Kymera Therapeutics Inc (KYMR, Financial) in one year is $20.35, suggesting a downside of 33.69% from the current price of $30.69. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Kymera Therapeutics Inc (KYMR) Summary page.
KYMR Key Business Developments
Release Date: February 27, 2025
- Revenue: $7.4 million, all from Sanofi collaboration.
- R&D Expenses: $71.8 million, including $6.8 million in non-cash stock-based compensation.
- Adjusted Cash R&D Spend: $65 million, a 23% increase from the previous quarter.
- G&A Expenses: $16.3 million, including $7 million in non-cash stock-based compensation.
- Adjusted Cash G&A Spend: $9.3 million, a 13% increase from the previous quarter.
- Cash Balance: $851 million, providing a runway into mid-2027.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Kymera Therapeutics Inc (KYMR, Financial) successfully delivered on all key priorities for 2024, including the completion of IND-enabling studies for STAT6 and TYK2 programs.
- The company has a strong cash position with $851 million, providing a runway into mid-2027, enabling execution on multiple data readouts.
- Kymera Therapeutics Inc (KYMR) is on track to report significant clinical data in 2025, including Phase I data for KT-621 and advancing KT-295 into the clinic.
- The company has a strategic collaboration with Sanofi, which is progressing with two ongoing Phase IIb studies in hidradenitis suppurativa (HS) and atopic dermatitis (AD).
- Kymera Therapeutics Inc (KYMR) is committed to developing an industry-leading immunology pipeline featuring innovative oral small molecule therapies, aiming to provide biologics-like efficacy with the convenience of an oral pill.
Negative Points
- The company faces risks and uncertainties that may cause actual results to differ materially from projections, as highlighted in their forward-looking statements.
- Kymera Therapeutics Inc (KYMR) has high R&D expenses, with a 23% sequential increase in adjusted cash R&D spend from the third quarter.
- The Phase 1b trial for KT-621 in atopic dermatitis is a small single-arm open-label trial, which may limit the ability to assess dose response and efficacy comprehensively.
- The company is transitioning to a video format for earnings calls, which may not be well-received by all stakeholders.
- There is uncertainty regarding the translation of preclinical data to clinical outcomes, particularly in novel targets like STAT6 and TYK2.
